MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$7,837,830
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Sale of short-term investments
Stock appreciation rights compen...
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Net loss
Payment of fees for issuance of ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-31,966,141
-19,867,760
-10,091,496
-27,425,907
Stock-based compensation
1,859,089
2,371,179
3,607,554
7,926,448
Stock appreciation rights compensation
4,019,150
1,028,815
-
27,649
Issuance of restricted common stock
-
905,226
-
-
Realized loss/(gain) on short-term investments
-47,162
-107,924
-81,439
110,156
Fair value changes on stock appreciation rights
-
-
216,640
-
Unrealized loss/(gain) on short-term investments
-707,354
256,321
-
141,934
Prepaid expenses and other assets
319,869
7,500
493,119
-411,834
Accounts payable
840,246
115,842
91,191
-2,768,652
Accrued expenses
150,000
1,125,087
-36,140
-2,388,191
Other receivable
-201,298
-
212,210
-
Net cash used in operating activities
-24,673,921
-14,596,223
-6,721,856
-24,468,909
Purchase of short-term investments
174,270,466
82,785,269
233,932
809,375
Sale of short-term investments
56,628,855
5,855,719
6,986,921
22,847,630
Net cash (used in)/provided by investing activities
-117,641,611
-76,929,550
6,752,989
22,038,255
Proceeds from issuance of common stock
159,999,996
93,637,829
-
-
Payment of fees for issuance of common stock
9,817,890
-
-
-
Proceeds from options exercised for common stock
101,497
-
-
0
Proceeds from warrants exercised for common stock
1,683
-
-
-
Atm fees
131,924
0
0
73,021
Net cash provided/(used in) by financing activities
150,153,362
93,637,829
0
-73,021
Net increase/(decrease) in cash and cash equivalents
7,837,830
2,112,056
31,133
-2,503,675
Cash and cash equivalents at beginning of the period
3,496,540
1,384,484
3,857,026
-
Cash and cash equivalents at end of the period
11,334,370
3,496,540
1,384,484
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock
$159,999,996
Proceeds from options
exercised for common stock
$101,497
Proceeds from warrants
exercised for common stock
$1,683
Net cash
provided/(used in) by financing...
$150,153,362
(205730.38%↑ Y/Y)
Canceled cashflow
$9,949,814
Net
increase/(decrease) in cash and cash...
$7,837,830
(413.05%↑ Y/Y)
Canceled cashflow
$142,315,532
Payment of fees for
issuance of common stock
$9,817,890
Atm fees
$131,924
(80.67%↑ Y/Y)
Sale of short-term
investments
$56,628,855
(147.85%↑ Y/Y)
Stock appreciation
rights compensation
$4,019,150
(14436.33%↑ Y/Y)
Stock-based compensation
$1,859,089
(-76.55%↓ Y/Y)
Accounts payable
$840,246
(130.35%↑ Y/Y)
Unrealized loss/(gain) on
short-term investments
-$707,354
(-598.37%↓ Y/Y)
Other receivable
-$201,298
Accrued expenses
$150,000
(106.28%↑ Y/Y)
Realized loss/(gain) on
short-term investments
-$47,162
(-142.81%↓ Y/Y)
Net cash (used
in)/provided by investing...
-$117,641,611
(-633.81%↓ Y/Y)
Net cash used in
operating activities
-$24,673,921
(-0.84%↓ Y/Y)
Canceled cashflow
$56,628,855
Canceled cashflow
$7,824,299
Purchase of short-term
investments
$174,270,466
(21431.49%↑ Y/Y)
Net loss
-$31,966,141
(-16.55%↓ Y/Y)
Prepaid expenses and
other assets
$319,869
(177.67%↑ Y/Y)
Buy us a coffee
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)